Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-positive Lesions in Patients with Metastatic Breast Cancer
Overview
Authors
Affiliations
We performed a feasibility study to determine the optimal dosage and time of administration of the monoclonal antibody zirconium-89 ((89)Zr)-trastuzumab to enable positron emission tomography (PET) imaging of human epidermal growth factor receptor 2 (HER2)-positive lesions. Fourteen patients with HER2-positive metastatic breast cancer received 37 MBq of (89)Zr-trastuzumab at one of three doses (10 or 50 mg for those who were trastuzumab-naive and 10 mg for those who were already on trastuzumab treatment). The patients underwent at least two PET scans between days 2 and 5. The results of the study showed that the best time for assessment of (89)Zr-trastuzumab uptake by tumors was 4-5 days after the injection. For optimal PET-scan results, trastuzumab-naive patients required a 50 mg dose of (89)Zr-trastuzumab, and patients already on trastuzumab treatment required a 10 mg dose. The accumulation of (89)Zr-trastuzumab in lesions allowed PET imaging of most of the known lesions and some that had been undetected earlier. The relative uptake values (RUVs) (mean +/- SEM) were 12.8 +/- 5.8, 4.1 +/- 1.6, and 3.5 +/- 4.2 in liver, bone, and brain lesions, respectively, and 5.9 +/- 2.4, 2.8 +/- 0.7, 4.0 +/- 0.7, and 0.20 +/- 0.1 in normal liver, spleen, kidneys, and brain tissue, respectively. PET scanning after administration of (89)Zr-trastuzumab at appropriate doses allows visualization and quantification of uptake in HER2-positive lesions in patients with metastatic breast cancer.
A Site-Specific MiniAp4-Trastuzumab Conjugate Prevents Brain Metastasis.
Masmudi-Martin M, Oller-Salvia B, Perea M, Teixido M, Valiente M, Giralt E Mol Pharm. 2025; 22(3):1384-1395.
PMID: 39924896 PMC: 11881140. DOI: 10.1021/acs.molpharmaceut.4c01091.
Novel Molecular Classification of Breast Cancer with PET Imaging.
Toan N Medicina (Kaunas). 2025; 60(12.
PMID: 39768978 PMC: 11678748. DOI: 10.3390/medicina60122099.
Movahed F, Navaei O, Taghlidi S, Nurzadeh M, Gharaati M, Rabiei M Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39751821 DOI: 10.1007/s00210-024-03691-7.
Radiopharmaceuticals and their applications in medicine.
Zhang S, Wang X, Gao X, Chen X, Li L, Li G Signal Transduct Target Ther. 2025; 10(1):1.
PMID: 39747850 PMC: 11697352. DOI: 10.1038/s41392-024-02041-6.
Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases.
Pan S, Gadrey J, Sammons S, Lin N, Tolaney S, Tarantino P Ther Adv Med Oncol. 2024; 16:17588359241292266.
PMID: 39529890 PMC: 11552056. DOI: 10.1177/17588359241292266.